Bristol Myers Squibb, shared a post on LinkedIn:
“This year’s EULAR – European Alliance of Associations for Rheumatology (EULAR 2026) offers a venue to unveil emerging data and collaborate with specialists across the globe. As part of this collaboration, leading global scientific experts and clinicians will come together to foster scientific exchange on the potential of CAR T cell therapy through the Autoimmunity Cell Therapy Network (ACTioN) Scientific Forum.
With an unwavering commitment to transforming the treatment landscape in hopes of expanding possibilities for those living with autoimmune diseases, we stand at the forefront of CAR T cell therapy research. Together with members of ACTioN, we are advancing science and assessing the potential future of autoimmune care.
Learn more.”
Proceed to the video attached to the post.
Other articles about Bristol Myers Squibb on OncoDaily.